Study Assessing Metabolism, Excretion and Pharmacokinetics of a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor in Patients With Solid Metastatic Tumours

This study has been completed.
KuDOS Pharmaceuticals Limited
Information provided by:
AstraZeneca Identifier:
First received: March 5, 2008
Last updated: January 13, 2009
Last verified: January 2009

Open, non-randomized, radiolabelled, single centre study designed to characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg [14C]-radiolabelled AZD2281 (KU-0059436) in patients with advanced or metastatic solid tumours.

Condition Intervention Phase
Neoplasm Metastasis
Drug: AZD2281
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open, Non-Randomized, Single Centre Phase I Study to Assess the Metabolism, Excretion and Pharmacokinetics of a Single Oral 100 mg Dose of [14C]-AZD2281 (KU-0059436) in Patients With Advanced or Metastatic Solid Tumours Refractory to Standard Treatments

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To characterize the metabolism, excretion and pharmacokinetics of a single oral dose of 100 mg [14C]-radiolabelled AZD2281 (KU-0059436) in patients with advanced or metastatic solid tumours, assessed by blood, urine and faecal sampling [ Time Frame: Various timepoints ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the safety and tolerability of AZD2281 (KU-0059436) by assessment of adverse events, laboratory findings and vital signs. [ Designated as safety issue: Yes ]
  • To provide plasma and excreta samples for future studies to investigate metabolite profiles and characterize human metabolites [ Designated as safety issue: No ]
  • To make a preliminary evaluation of clinical response as measured by objective tumour response rates at various timepoints. [ Designated as safety issue: No ]

Estimated Enrollment: 6
Study Start Date: April 2008
Study Completion Date: October 2008
Primary Completion Date: October 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: AZD2281
    100mg Oral Dose
    Other Name: Olaparib

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed advanced or metastatic tumour, refractory to standard therapies

Exclusion Criteria:

  • Anti-cancer therapy including chemotherapy, radiotherapy (excluding palliative radiotherapy), endocrine therapy, immunotherapy or use of other investigational agents within 4 weeks prior to study entry.
  • Patients may continue the use of LHRH agonists for cancer, bisphosphonates for bone disease and corticosteroids provided the dose is stable before and during the study.
  • Females will be able to continue to take hormone replacement therapy
  Contacts and Locations
Please refer to this study by its identifier: NCT00633269

United Kingdom
Research Site
London, United Kingdom
Sponsors and Collaborators
KuDOS Pharmaceuticals Limited
Study Director: James Carmichael, BSc, MBChB, MD, FRCP KuDOS Pharmaceuticals, Ltd
Principal Investigator: Johann deBono, MD, FRCP, MSc PhD Royal Marsden Hospital, Surrey, UK
  More Information

No publications provided

Responsible Party: Jim Carmichael - CMO, AstraZeneca Identifier: NCT00633269     History of Changes
Other Study ID Numbers: D0810C00010, KU36-37
Study First Received: March 5, 2008
Last Updated: January 13, 2009
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by AstraZeneca:
Poly(ADP ribose) polymerases
Metastatic Solid Tumours

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes processed this record on April 23, 2014